MA32481B1 - Compositions et procédés d'utilisation pour des anticorps thérapeutiques - Google Patents

Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Info

Publication number
MA32481B1
MA32481B1 MA33525A MA33525A MA32481B1 MA 32481 B1 MA32481 B1 MA 32481B1 MA 33525 A MA33525 A MA 33525A MA 33525 A MA33525 A MA 33525A MA 32481 B1 MA32481 B1 MA 32481B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
antibodies
therapeutic antibodies
baffr
Prior art date
Application number
MA33525A
Other languages
Arabic (ar)
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32481(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32481B1 publication Critical patent/MA32481B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur des anticorps qui se lient de façon spécifique au récepteur baff (baffr). Plus spécifiquement, l'invention porte sur des anticorps qui sont des antagonistes de baffr avec une activité de déplétion des cellules b in vivo, et sur des compositions et procédés d'utilisation pour lesdits anticorps pour traiter des troubles pathologiques qui peuvent être traités par destruction ou déplétion des cellules b, tels que le lupus érythémateux systémique ou la polyarthrite rhumatoïde ou d'autres maladies auto-immunes, des lymphomes, des leucémies ou des myélomes.
MA33525A 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques MA32481B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15
PCT/EP2009/059030 WO2010007082A1 (fr) 2008-07-17 2009-07-15 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Publications (1)

Publication Number Publication Date
MA32481B1 true MA32481B1 (fr) 2011-07-03

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33525A MA32481B1 (fr) 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Country Status (40)

Country Link
US (3) US8106163B2 (fr)
EP (1) EP2315780B8 (fr)
JP (2) JP5767109B2 (fr)
KR (2) KR101545795B1 (fr)
CN (1) CN102119174B (fr)
AR (1) AR072749A1 (fr)
AU (1) AU2009272771B2 (fr)
BR (1) BRPI0915928B8 (fr)
CA (1) CA2730063C (fr)
CL (1) CL2011000086A1 (fr)
CR (1) CR11863A (fr)
CU (1) CU23878B1 (fr)
CY (1) CY1116800T1 (fr)
DK (1) DK2315780T3 (fr)
DO (1) DOP2011000016A (fr)
EA (1) EA024492B1 (fr)
EC (1) ECSP11010761A (fr)
ES (1) ES2547270T3 (fr)
GE (1) GEP20146129B (fr)
HR (1) HRP20151227T1 (fr)
HU (1) HUE025778T2 (fr)
IL (1) IL210485A (fr)
JO (1) JO3149B1 (fr)
MA (1) MA32481B1 (fr)
MX (1) MX2011000616A (fr)
MY (1) MY158980A (fr)
NI (1) NI201100017A (fr)
NZ (1) NZ590057A (fr)
PE (1) PE20110563A1 (fr)
PL (1) PL2315780T3 (fr)
PT (1) PT2315780E (fr)
RS (1) RS54299B1 (fr)
SG (1) SG193805A1 (fr)
SI (1) SI2315780T1 (fr)
SM (1) SMP201100010B (fr)
SV (1) SV2011003807A (fr)
TW (1) TWI508742B (fr)
UY (1) UY31987A (fr)
WO (1) WO2010007082A1 (fr)
ZA (1) ZA201008952B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2012076670A2 (fr) 2010-12-10 2012-06-14 Novartis Ag Formulation d'anticorps
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
EP3026064B1 (fr) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Anticorps pour le traitement du cancer exprimant du claudin 6
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
CA2934965A1 (fr) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Nouveaux anticorps anti-baff
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
BR112018015272A2 (pt) 2016-02-10 2018-12-18 Novartis Ag uso de inibidores da atividade ou função de pi3k para o tratamento de síndrome de sjögren primária
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
EP3559035A1 (fr) 2016-12-21 2019-10-30 TeneoBio, Inc. Anticorps à chaîne lourde uniquement anti-bcma
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
EP3630843A2 (fr) 2017-05-24 2020-04-08 ALS Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
LT3823990T (lt) * 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
JPWO2020202839A1 (fr) * 2019-03-29 2020-10-08
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CA3160207A1 (fr) 2019-11-06 2021-05-14 Novartis Ag Traitement du syndrome de sjogren
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
JP7834711B2 (ja) 2020-08-04 2026-03-24 ノバルティス アーゲー Ｂ細胞悪性腫瘍の治療
IL300087A (en) 2020-08-04 2023-03-01 Novartis Ag Treatment of CLL
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
US20250215081A1 (en) * 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
US20240228644A1 (en) * 2021-05-04 2024-07-11 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
US20240239911A1 (en) * 2021-05-04 2024-07-18 Novartis Ag Treatment for lupus nephritis using anti-baffr antibodies
JP2024537772A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
EP4777835A1 (fr) * 2023-09-11 2026-07-22 ABSCI Corporation Procédés à haut rendement pour caractérisation cinétique, quantification et optimisation d'anticorps et d'expression de fragments d'anticorps dans des bactéries
WO2025131888A1 (fr) 2023-12-19 2025-06-26 Basf Se Polyalkylène imines alcoxylées modifiées ou polyamines alcoxylées modifiées
WO2025221674A1 (fr) * 2024-04-15 2025-10-23 Eli Lilly And Company Anticorps bispécifiques baffr x cd3 et procédés d'utilisation
WO2026064677A2 (fr) * 2024-09-20 2026-03-26 Paragon Therapeutics, Inc. Polypeptides se liant au récepteur baff, compositions et leurs procédés d'utilisation
CN122302060A (zh) * 2024-12-31 2026-06-30 北京福元医药股份有限公司 靶向baffr的抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043608B (en) * 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
WO2008008482A2 (fr) * 2006-07-13 2008-01-17 Genentech, Inc. Polypeptides de liaison à br3 modifiés

Also Published As

Publication number Publication date
HRP20151227T1 (hr) 2015-12-18
KR101545795B1 (ko) 2015-08-19
UY31987A (es) 2010-02-26
WO2010007082A1 (fr) 2010-01-21
CL2011000086A1 (es) 2011-07-01
EA024492B1 (ru) 2016-09-30
CU23878B1 (es) 2013-04-19
JO3149B1 (ar) 2017-09-20
CU20110013A7 (es) 2012-06-21
AU2009272771B2 (en) 2012-09-20
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
NI201100017A (es) 2012-08-17
TWI508742B (zh) 2015-11-21
ZA201008952B (en) 2012-01-25
SI2315780T1 (sl) 2015-11-30
HK1150839A1 (en) 2012-01-13
AR072749A1 (es) 2010-09-15
PE20110563A1 (es) 2011-08-29
CN102119174B (zh) 2015-01-21
JP2015133983A (ja) 2015-07-27
EP2315780B1 (fr) 2015-08-19
EA201100191A1 (ru) 2011-08-30
GEP20146129B (en) 2014-08-11
KR101314369B1 (ko) 2013-10-10
KR20130098432A (ko) 2013-09-04
SMP201100010B (it) 2011-09-09
IL210485A0 (en) 2011-03-31
CA2730063A1 (fr) 2010-01-21
IL210485A (en) 2015-03-31
KR20110020914A (ko) 2011-03-03
RS54299B1 (sr) 2016-02-29
BRPI0915928B8 (pt) 2021-05-25
PT2315780E (pt) 2015-11-30
US20120195913A1 (en) 2012-08-02
BRPI0915928A2 (pt) 2015-11-03
AU2009272771A1 (en) 2010-01-21
DOP2011000016A (es) 2011-02-15
PL2315780T3 (pl) 2016-01-29
DK2315780T3 (en) 2015-10-19
US8106163B2 (en) 2012-01-31
CR11863A (es) 2011-02-11
NZ590057A (en) 2012-08-31
EP2315780B8 (fr) 2015-09-23
JP5767109B2 (ja) 2015-08-19
MX2011000616A (es) 2011-02-24
CY1116800T1 (el) 2017-03-15
ES2547270T3 (es) 2015-10-05
EP2315780A1 (fr) 2011-05-04
BRPI0915928B1 (pt) 2020-10-20
JP6077587B2 (ja) 2017-02-08
HUE025778T2 (en) 2016-05-30
SG193805A1 (en) 2013-10-30
US9382326B2 (en) 2016-07-05
ECSP11010761A (es) 2011-02-28
TW201006493A (en) 2010-02-16
MY158980A (en) 2016-11-30
SV2011003807A (es) 2011-03-23
CA2730063C (fr) 2017-04-18
CN102119174A (zh) 2011-07-06
JP2011527896A (ja) 2011-11-10
US20100021452A1 (en) 2010-01-28
US9340620B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
JO3149B1 (ar) تراكيب وطرق إستعمال للأجسام المضادة العلاجية
EP2322557A3 (fr) Compositions et procédés pour traiter des maladies prolifératives
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MY160590A (en) Cd127 binding proteins
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
IL215026A (en) 1r7zb antagonist, methods and compounds @ which include @ the same
EA202092589A3 (ru) Cxcr2-связывающие полипептиды
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX389758B (es) Ratones con genes insertados de sirpa-il15 humanizadas y métodos para usarlos
WO2012118750A3 (fr) Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201100452A1 (ru) Лечение воспалительных состояний
MX356264B (es) Composiciones útiles como arenas sanitarias para animales.
WO2006125640A3 (fr) Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
EP2561073A4 (fr) Vecteurs aav ciblant le système nerveux central et leurs procédés d'utilisation
WO2013123432A3 (fr) Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MX337352B (es) Nuevos agentes anti-inflamatorios.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
EP2465922A3 (fr) Cellules souches mésenchymateuses exprimant un récepteur TNF-a